MSD-CYP11B2
| Target | CYP11B2 |
| Mode of action | Inhibitor |
| Control | MSD-CYP11B2 Negative control |
| Recommended cellular usage concentration | 25 - 100 nM |
| In vivo use | Yes |
| Synonyms | CYP11B2-IN-1 |
| Donated by | MSD |
Probe criteria
| Inhibitor/agonist potency: goal is < 100 nM (IC50, Kd>/sub>) | N/A |
| Selectivity within target family: > 30-fold | Surpasses criterion: human CYP11B1: IC50 = 142 nM (Assay using V79 cell lines); 61x more selective for CYP11B2 compared to CYP11B1human CYP19A1: IC50 = 1021 nM |
| Selectivity outside target family | Closest off-targets (Panlabs): ADRA2B: IC50 = 4.7 µM @ 10 µM; HTR2B: IC50 = 5.33 µM @ 10 µM; ADRB1: IC50 = 9.62 µM @ 10 µM;Shows off-target activity in the PDSP scan on the same targets as the Panlabs screen: ADRA2C (Ki = 625.6 nM), ADRA2B (Ki = 1439.13 nM), HTR2B (Ki = 1537.45 nM), ADRB1 (Ki = 2370.28 nM), ADRA2A (Ki = 2606.75 nM) |
| On target cell activity for cell-based targets: goal is < 1 µM IC50/EC50 | Surpasses criterion: human CYP11B2: IC50 = 2.3 nM (Assay using V79 cell lines) |
| Control compound (100 times less potent than the probe) | Surpasses criterion: For the MSD-CYP11B2 Negative control: human CYP11B2: IC50 > 10000 nM (Assay using V79 cell lines); Clean PDSP scan except for activity on HTR2B (Ki = 1073.0 nM), HTR6 (Ki = 3060.55 nM) |